Navigation Links
ARCADIS' Jane Staveley to Moderate Congressional Briefing on Pharmaceuticals in Drinking Water
Date:9/14/2010

DENVER, Sept. 14 /PRNewswire/ -- Jane Staveley, a Principal Environmental Scientist for ARCADIS (EURONEXT: ARCAD), the international consultancy, design, engineering and management services company, will moderate a distinguished panel of experts on the topic of "Pharmaceuticals in Our Water: Concerns and Responses" during a briefing in the Rayburn House Office Building today, September 14. The briefing will be held from noon to 1:30 p.m. and is presented by the American Chemical Society's Science & the Congress Project, the Society for Risk Analysis and the Society of Toxicology, with honorary co-host, the House Science and Technology Committee.

(Logo:  http://photos.prnewswire.com/prnh/20090710/LA44654LOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20090710/LA44654LOGO)

With a focus on the presence of pharmaceuticals in waterways and drinking water throughout the United States, the briefing is designed to explore what is known about the relative contributions from different types of drugs, their persistence in the environment, and the best methods of drug disposal to reduce the amount getting into the environment.  

"I look forward to guiding the panelists in this important discussion as we explore what is known and still unknown about the potential impacts of water-borne pharmaceuticals on human health and ecological receptors," said Staveley. "We also will discuss what steps can be taken to maintain the health benefits of drugs, while at the same time mitigating any unintended consequences from their presence in our water."

Renowned scientists comprising the panel include Mae Wu from the Natural Resources Defense Council; Shane Snyder from the University of Arizona; Sierra Fletcher from the Product Stewardship Institute; and Richard Williams, formerly of Pfizer, Inc.

Staveley brings a wealth of knowledge to her role as moderator, given her more than 30 years of experience in both the public and private sectors working on myriad environmental issues. In addition to her role with ARCADIS, she is currently the President of the Society of Environmental Toxicology and Chemistry (SETAC) and is active in SETAC's advisory group on Pharmaceuticals in the Environment.

For more information, please contact Jeanna Blatt of ARCADIS at 303.471.3485 or Jeanna.Blatt@ARCADIS-US.com.

About ARCADIS:

ARCADIS is an international company providing consultancy, design, engineering and management services in infrastructure, water, environment and buildings. We enhance mobility, sustainability and quality of life by creating balance in the built and natural environment. ARCADIS develops, designs, implements, maintains and operates projects for companies and governments. With 15,000 employees and over $2.4 billion in revenues, the company has an extensive international network supported by strong local market positions. ARCADIS supports UN-HABITAT with knowledge and expertise to improve the quality of life in rapidly growing cities around the world. Visit us at: www.arcadis-us.com.


'/>"/>
SOURCE ARCADIS
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine
2. New Data Show CIMZIA(R) (certolizumab pegol) Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients
3. PTSD Associated With Higher Alzheimers/Dementia Risk; Moderate Alcohol Consumption May Lower it
4. Horizon Therapeutics HZT-501 Significantly Reduces Incidence of NSAID-Induced Upper Gastrointestinal Ulcers in Patients With Mild-to-Moderate Pain
5. Pelleve Receives FDA Clearance for the Treatment of Mild to Moderate Facial Wrinkles
6. New Studies Show Popular Heartburn Medications Moderate the Effect of Taking Widely Prescribed Heart Drug
7. Acanya(TM) Gel, a New Treatment for Moderate to Severe Acne, Launched by Coria Laboratories
8. Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant
9. FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain
10. Study Shows Potential Benefits of Xolair(R) in Treating Children Suffering from Moderate or Severe Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids
11. Cepheid Molecular Diagnostic Test for Positive Blood Culture Bottles Categorized Moderate Complexity by FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 ... Markets has announced the addition of the " ... offering. This ... and provides an updated review, including its applications in ... the total market, which includes three main industries: pharmaceutical ...
(Date:6/24/2016)... 24, 2016 Research and Markets has ... Companion Diagnostic Tests" report to their offering. ... Diagnostics The World Market for Companion Diagnostics ... diagnostics. Market analysis in the report includes the following: ... Vitro Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced today ... its e-clinical software solution of choice.  This latest ... possible value to their clients by offering a ... preferred relationship establishes nowEDC as the EDC platform ... MedSource,s full-service clients.  "nowEDC has long been a ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Those who ... with these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, ... Marne, Michigan, has released tools for healthy coping following a traumatic event. , Trauma ...
Breaking Medicine News(10 mins):